Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026

IRWD vs SIGA: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

IRWD Wins Head-to-Head Institutional Verdict (3–3 across 6 Pillars · 7–3 Matrix Metrics)

IRWD Overall Winner 6-Pillar Tally: IRWD 3 – 3 SIGA Matrix Metrics: IRWD 7 – 3 SIGA

As of Nov 19, 2026, Ironwood Pharmaceuticals, Inc. - Class A (IRWD) is the stronger overall head-to-head candidate over SIGA Technologies Inc. (SIGA) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). IRWD carries a Unified Composite Score of 37.5/100 (SELL) at $4.71 (12.3x Forward P/E, 62.9% operating margin), whereas SIGA carries 47.5/100 (HOLD) at $2.65 (2.5x Forward P/E, -14.2% operating margin).

  • Composite vs. Pillar Nuance: While SIGA currently prints a higher short-term Unified Composite Score (47.5/100 HOLD vs. IRWD 37.5/100 SELL), IRWD captures the overall institutional head-to-head verdict (7–3 matrix metrics and 3–3 across the 6 pillars) due to superior fundamental profitability (62.9% vs. -14.2% operating margin) and revenue trajectory (+9.0% vs. -49.7% YoY).
  • Technical & Structure Timing Caution: IRWD trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 67.1); meanwhile SIGA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About IRWD vs SIGA
IRWD NASDAQ Head-to-Head Winner
Ironwood Pharmaceuticals, Inc. - Class A
Pharmaceutical Preparations
$4.71
-1.46% 1D
Market Cap $791.3M
TTM Revenue $400M
Forward P/E 12.3x
Beta / 30D Vol 1.31β · 54% Vol
Unified Composite Score
37.5 / 100 SELL
Tech 50.0 Fund 34.0 Flow 67.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 67
RSI-14: 67.1 · SMA20: $4.18 · SMA50: $4.02
SIGA NASDAQ
SIGA Technologies Inc.
Pharmaceutical Preparations
$2.65
-5.36% 1D
Market Cap $187.9M
TTM Revenue $52M
Forward P/E 2.5x
Beta / 30D Vol 0.75β · 65% Vol
Unified Composite Score
47.5 / 100 HOLD
Tech 40.0 Fund 56.0 Flow 69.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -0.6%), weak momentum, RSI 37
RSI-14: 36.7 · SMA20: $3.02 · SMA50: $3.14

6-Pillar Scorecard Institutional Category Breakdown (IRWD 3 – 3 SIGA)

Columns: Metric · IRWD · SIGA
1. Valuation Multiples SIGA
Forward P/E 12.3x 2.5x
Trailing P/E 5.3x N/M
PEG Ratio N/M 3.37x
EV / Revenue 2.6x 1.4x
2. Growth & Scale IRWD
Revenue Growth (YoY) +9.0% -49.7%
Earnings Growth (YoY) +57.0% -65.3%
TTM Revenue (USD) $400M $52M
Market Cap $791.3M $187.9M
3. Profitability & Quality IRWD
Gross Margin 76.4% 23.4%
Operating Margin 62.9% -14.2%
Net Profit Margin 37.4% 1.3%
Return on Equity (ROE) -574.7% 0.4%
4. Balance Sheet & Cash Flow IRWD
Cash Generation (TTM) $205M -$12M
Cash Flow Margin 51.3% -22.1%
Net Cash / Leverage $250M Net Debt $116M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning SIGA
Options Structure Phase CONSOLIDATION CONSOLIDATION
Current IV / %ile 73.8% (14th %ile) 81.4% (8th %ile)
Put/Call OI Skew N/A 0.04x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Neutral DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat SIGA
OpEx & R&D Intensity 13.5% of Rev ($54M) 37.6% of Rev ($20M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat High-Margin Pricing Power Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Drug Manufacturers - Specialty & Generic Operator Drug Manufacturers - Specialty & Generic Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: IRWD (7) vs SIGA (3)
Institutional Metric IRWD SIGA Criterion Row Edge
Market Capitalization
Scale
$791.3M $187.9M Larger Scale IRWD
Trailing P/E Ratio
Valuation
5.3x N/M Lower Multiple IRWD
Forward P/E Ratio
Valuation
12.3x 2.5x Lower Multiple SIGA
Revenue Growth (YoY)
Growth
+9.0% -49.7% Higher Growth IRWD
Operating Margin (TTM)
Profitability
62.9% -14.2% Higher Margin IRWD
Net Profit Margin
Profitability
37.4% 1.3% Higher Margin IRWD
Return on Equity (ROE)
Capital Efficiency
-574.7% 0.4% Higher ROE SIGA
52-Week Range Position
Momentum
62% ($3–$6) 3% ($3–$7) Stronger Trend IRWD
Beta / 30D Volatility
Risk Regime
1.31β · 54% Vol 0.75β · 65% Vol Lower Realized Risk IRWD
Unified Institutional Score
Composite Signal
37.5 / 100 (SELL) 47.5 / 100 (HOLD) Higher Composite SIGA
Trailing 12M Revenue (USD)
Operating Scale
$400M $52M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
76.4% 23.4% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 2.6x EV/Rev 3.37x PEG · 1.4x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$205M ($250M Net Debt) -$12M ($116M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon IRWD +47.74 pp
IRWD: +32.68% · SIGA: -15.06%
3M Horizon IRWD +22.62 pp
IRWD: +9.79% · SIGA: -12.83%
6M Horizon IRWD +66.08 pp
IRWD: +22.34% · SIGA: -43.74%
1Y Horizon IRWD +107.06 pp
IRWD: +51.45% · SIGA: -55.61%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period IRWD Revenue SIGA Revenue IRWD Op. Margin SIGA Op. Margin Margin Leader
FY2018 $350M $480M -43.5% 74.4% SIGA
FY2019 $430M $30M 28.0% -8.7% IRWD
FY2020 $390M $120M 36.7% 67.6% SIGA
FY2021 $410M $130M 56.1% 66.7% SIGA
FY2022 $410M $110M 61.0% 38.5% IRWD
FY2023 $440M $140M -213.5% 59.8% SIGA
FY2024 $350M $140M 26.5% 50.4% SIGA
FY2025 $300M $90M 33.3% 25.1% IRWD

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
IRWD CONSOLIDATION
137d in phase · OBV NEUTRAL
Current IV 73.8%
IV Percentile 14th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact IRWD Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
SIGA CONSOLIDATION
33d in phase · OBV DISTRIBUTION
Current IV 81.4%
IV Percentile 8th %ile
Put/Call OI Skew 0.04x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact SIGA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
IRWD Moat Profile High-Margin Pricing Power Moat
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $791.3M market capitalization and 62.9% operating margin.
OpEx & R&D Reinvestment 13.5% of Rev ($54M)
90D Engineering Disclosures 0 Published
SIGA Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $187.9M market capitalization and -14.2% operating margin.
OpEx & R&D Reinvestment 37.6% of Rev ($20M)
90D Engineering Disclosures 0 Published

Investor FAQ IRWD vs SIGA Key Questions & Quantitative Answers

As of Nov 19, 2026, Ironwood Pharmaceuticals, Inc. - Class A (IRWD) is the stronger overall head-to-head candidate over SIGA Technologies Inc. (SIGA) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). IRWD carries a Unified Composite Score of 37.5/100 (SELL) at $4.71 (12.3x Forward P/E, 62.9% operating margin), whereas SIGA carries 47.5/100 (HOLD) at $2.65 (2.5x Forward P/E, -14.2% operating margin). Composite vs. Pillar Nuance: While SIGA currently prints a higher short-term Unified Composite Score (47.5/100 HOLD vs. IRWD 37.5/100 SELL), IRWD captures the overall institutional head-to-head verdict (7–3 matrix metrics and 3–3 across the 6 pillars) due to superior fundamental profitability (62.9% vs. -14.2% operating margin) and revenue trajectory (+9.0% vs. -49.7% YoY). Technical & Structure Timing Caution: IRWD trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 67.1); meanwhile SIGA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 36.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

IRWD leads the Growth & Scale pillar: IRWD posts +9.0% YoY revenue growth and +57.0% YoY earnings growth on $400M TTM revenue (76.4% gross margin, 62.9% operating margin), compared with SIGA at -49.7% YoY revenue growth and -65.3% YoY earnings growth on $52M TTM revenue (23.4% gross margin, -14.2% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), IRWD cumulative revenue shifted -14.3% while SIGA shifted -81.2%. In operating R&D and SG&A reinvestment, IRWD deploys 13.5% of Rev ($54M) (0 90-day corporate R&D disclosures) versus 37.6% of Rev ($20M) (0 disclosures) for SIGA.

SIGA screens cheaper on headline valuation multiples. IRWD trades at 12.3x Forward P/E, 5.3x Trailing P/E, N/M PEG, and 2.6x EV/Revenue (51.3% FCF margin), whereas SIGA trades at 2.5x Forward P/E, N/M Trailing P/E, 3.37x PEG, and 1.4x EV/Revenue (-22.1% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against IRWD (-574.7% ROE) versus SIGA (0.4% ROE) capital efficiency.

In options market volatility and institutional positioning, IRWD carries 73.8% implied volatility (14th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.31β · 54% Vol realized risk). By comparison, SIGA carries 81.4% implied volatility (8th %ile, Compressed (<25th %ile)), a 0.04x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.75β · 65% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.